Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib vs Best Available Therapy in Myelofibrosis (PERSIST-1)
NCT01773187Phase 3Terminated
- Sponsor
- CTI BioPharma Corp.
- Start
- Jan 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of pacritinib in myelofibrosis (MF), sponsored by CTI BioPharma Corp.. Started Jan 2013; status: terminated.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01773187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01773187.